Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMELINA cardiovascular and renal outcomes study of linagliptin in high-risk type 2 diabetes
NL-OMON44703Phase 4Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Primary composite cardiovascular endpoint and Expanded primary objective composite endpoint. Started Aug 2014; status: active, not recruiting.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON44703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44703.